Pharmacokinetics in children

The clearance of ipilimumab increases with increased bodyweight. The average clearance in children aged 12-18 years is 8.72 ml/hour

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Renal impaiment in children > 3 months

No information available on dose adjustment in renal impairment.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects

No information is present at this moment.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions in children

Research data: in children (≥ 12 yrs, monotherapy), only start therapy after very careful consideration because of the very small amount of safety data and lack of data on long-term treatment.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

Reference

1. Bristol-Meyers Squibb Pharma EEIG, SmPC Yervoy (EU1/11/698/001-002) 30-07-2018, www. geneesmiddeleninformatiebank.nl

Changes

Therapeutic Drug Monitoring

Overdose